179 related articles for article (PubMed ID: 34924279)
1. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?
Icard P; Simula L; Wu Z; Berzan D; Sogni P; Dohan A; Dautry R; Coquerel A; Lincet H; Loi M; Fuks D
Drug Resist Updat; 2021 Dec; 59():100790. PubMed ID: 34924279
[TBL] [Abstract][Full Text] [Related]
2. The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications.
Icard P; Simula L; Fournel L; Leroy K; Lupo A; Damotte D; Charpentier MC; Durdux C; Loi M; Schussler O; Chassagnon G; Coquerel A; Lincet H; De Pauw V; Alifano M
Drug Resist Updat; 2022 Jul; 63():100852. PubMed ID: 35849943
[TBL] [Abstract][Full Text] [Related]
3. How Phosphofructokinase-1 Promotes PI3K and YAP/TAZ in Cancer: Therapeutic Perspectives.
Simula L; Alifano M; Icard P
Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626081
[TBL] [Abstract][Full Text] [Related]
4. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma.
Feng J; Li J; Wu L; Yu Q; Ji J; Wu J; Dai W; Guo C
J Exp Clin Cancer Res; 2020 Jul; 39(1):126. PubMed ID: 32631382
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
6. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
[TBL] [Abstract][Full Text] [Related]
7. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
8. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: A study of effectiveness, safety and costs.
Megías Vericat JE; García Marcos R; López Briz E; Gómez Muñoz F; Ramos Ruiz J; Martínez Rodrigo JJ; Poveda Andrés JL
Radiologia; 2015; 57(6):496-504. PubMed ID: 25857250
[TBL] [Abstract][Full Text] [Related]
9. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect.
Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Wu J; Wang X
Cell Death Dis; 2018 May; 9(5):549. PubMed ID: 29748591
[TBL] [Abstract][Full Text] [Related]
10. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
[TBL] [Abstract][Full Text] [Related]
11. Anti-Glycolytic Drugs in the Treatment of Hepatocellular Carcinoma: Systemic and Locoregional Options.
Pourbaghi M; Haghani L; Zhao K; Karimi A; Marinelli B; Erinjeri JP; Geschwind JH; Yarmohammadi H
Curr Oncol; 2023 Jul; 30(7):6609-6622. PubMed ID: 37504345
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
13. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway.
Yang X; Feng Y; Liu Y; Ye X; Ji X; Sun L; Gao F; Zhang Q; Li Y; Zhu B; Wang X
Phytomedicine; 2021 Jul; 87():153575. PubMed ID: 33984593
[TBL] [Abstract][Full Text] [Related]
14. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
15. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
16. Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death.
Li S; Li J; Dai W; Zhang Q; Feng J; Wu L; Liu T; Yu Q; Xu S; Wang W; Lu X; Chen K; Xia Y; Lu J; Zhou Y; Fan X; Mo W; Xu L; Guo C
Br J Cancer; 2017 Nov; 117(10):1518-1528. PubMed ID: 28926527
[TBL] [Abstract][Full Text] [Related]
17. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
18. Fructose-1,6-bisphosphate promotes PI3K and glycolysis in T cells?
Icard P; Alifano M; Donnadieu E; Simula L
Trends Endocrinol Metab; 2021 Aug; 32(8):540-543. PubMed ID: 34016523
[TBL] [Abstract][Full Text] [Related]
19. The epigallocatechin gallate derivative Y
Liao ZH; Zhu HQ; Chen YY; Chen RL; Fu LX; Li L; Zhou H; Zhou JL; Liang G
J Ethnopharmacol; 2020 Sep; 259():112852. PubMed ID: 32278759
[TBL] [Abstract][Full Text] [Related]
20. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
